---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-019332"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2022-10-06T23:59:59+00:00"
generated_at: "2026-06-23T05:09:15.892424+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Surrozen enters $12.5M upfront license deal with Boehringer Ingelheim for Fzd4 bispecific antibodies

## Summary
- Upfront payment of $12.5 million; eligible for up to $586.5M in development, regulatory, and commercial milestones.
- Royalties on net sales range from mid-single digit to low-double digit, subject to standard reductions.
- Boehringer Ingelheim leads development and commercialization of SZN-413 and other Fzd4 bispecifics for retinal diseases.
- 5-year exclusivity: Surrozen cannot develop Fzd4 bispecifics for eye diseases; BI restricted to eye diseases.
- Collaborative research period of one year (BI may extend 6 months) after which BI selects lead and back-up candidates.

## SEC filing metadata
- accession: 0000950170-22-019332
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2022-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017022019332/0000950170-22-019332-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017022019332/srzn-20220930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-019332
- JSON: https://secwatch.observer/filing/0000950170-22-019332.json
- Plain text: https://secwatch.observer/filing/0000950170-22-019332.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.